Insulin Glargine
- TRADE NAMES: Basaglar (Lilly); Lantus (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
- INDICATIONS: Diabetes (Type I or II)
- CLASS: Hormone analog, polypeptide
- HALF-LIFE: N/A
ACE inhibitors, Albuterol, Alcohol, Beta blockers, Clonidine, Clozapine, Corticosteroids, Danazol, Disopyramide, Diuretics, Epinephrine, Estrogens, Fibrates, Fluoxetine, Glucagon, Guanethidine, Isoniazid, Lithium, MAO inhibitors, Niacin, Olanzapine, Oral antidiabetic products, Oral Contraceptives, Pentamidine, Pentoxifylline, Phenothiazine derivatives, Pramlintide, Propoxyphene, Propranolol, Protease inhibitors, Reserpine, Salicylates, Somatostain analogs, Somatropin, Sulfonamide antibiotics, Terbutaline, Thyroid hormones
PREGNANCY CATEGORY: C
Soliqua is insulin glargine and lixisenatide; various forms of insulin are available - see other insulin profiles for reaction details.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of insulin glargine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric